Skip to main content
Benjamin Sulman, a scientist in ORNL’s Environmental Sciences Division, creates Earth system models that simulate how plants, microbes and soils interact and influence the cycling of carbon, water and nutrients in their environment. His work aims to helps researchers across disciplines better understand complex, rapidly changing ecosystems, including coastal wetlands and Arctic permafrost soils. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

As rising global temperatures alter ecosystems worldwide, the need to accurately simulate complex environmental processes under evolving conditions is more urgent than ever.

Innovation Crossroads Cohort 5 includes left to right: Caleb Alexander, DayLyte Batteries; Sam Evans, Unbound Water Technologies; Tommy Gibbons, Hempitecture; Shuchi “SK” Khurana, Addiguru; Forrest Shriver, Sentinel Devices; and Philip Stuckey, FC Renew.

Six science and technology innovators from across the United States will join the fifth cohort of Oak Ridge National Laboratory’s Innovation Crossroads program in June.

Balendra Sutharshan

In the mid-1980s, Balendra Sutharshan moved to Canada from the island nation of Sri Lanka. That move set Sutharshan on a path that had him heading continent-spanning collaborations and holding leadership posts at multiple Department of Energy

L-R: ORNL’s Omer Onar and Veda Galigekere with the dynamic wireless charging test bed at ORNL’s Grid Research Integration and Deployment Center. Credit: Carlos Jones, ORNL/U.S. Dept. of Energy

Consumer buy-in is key to the future of a decarbonized transportation sector in which electric vehicles largely replace today’s conventionally fueled cars and trucks.

Deborah Frincke, one of the nation’s preeminent computer scientists and cybersecurity experts, serves as associate laboratory director of ORNL’s National Security Science Directorate. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Deborah Frincke, one of the nation’s preeminent computer scientists and cybersecurity experts, serves as associate laboratory director of ORNL’s National Security Science Directorate. Credit: Carlos Jones/ORNL, U.S. Dept. of Energy

Brenda Smith, shown here working with a gas viscometer in her research lab, is one of several people concurrently researching the thermophysical properties of feedstock gas. Their research will support computational researchers who are designing processes to separate isotopes. Credit: Carlos Jones/ORNL, US Dept. of Energy

For years Brenda Smith found fulfillment working with nuclear batteries, a topic she’s been researching as a chemist at Oak Ridge National Laboratory.

Oak Ridge National Laboratory’s MENNDL AI software system can design thousands of neural networks in a matter of hours. One example uses a driving simulator to evaluate a network’s ability to perceive objects under various lighting conditions. Credit: ORNL, U.S. Dept. of Energy

The Department of Energy’s Oak Ridge National Laboratory has licensed its award-winning artificial intelligence software system, the Multinode Evolutionary Neural Networks for Deep Learning, to General Motors for use in vehicle technology and design.

Heavy-duty vehicles contribute 23% of transportation emissions of greenhouse gases and account for almost one-quarter of the fuel consumed annually in the U.S. Credit: Chris Bair/Unsplash

Through a consortium of Department of Energy national laboratories, ORNL scientists are applying their expertise to provide solutions that enable the commercialization of emission-free hydrogen fuel cell technology for heavy-duty

INCITE logo

The U.S. Department of Energy’s Innovative and Novel Computational Impact on Theory and Experiment, or INCITE, program is seeking proposals for high-impact, computationally intensive research campaigns in a broad array of science, engineering and computer science domains. 

Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy

A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.